NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumour mutation burden for high risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer.

Kai-Keen Shiu University College Hospital, NHS Foundation Trust, London, United Kingdom info_outline Kai-Keen Shiu, Yanrong Jiang, Mark Saunders, Jenny F. Seligmann, Timothy Iveson, Richard H. Wilson, Janet Shirley Graham, Khurum Hayat Khan, Anna-Maria Militello, Sandra Irvine, Temi Adedoyin, Rubina Begum, Reshma Bhat, William Wilson, Andrew Plumb, Austin Obichere, Manuel Rodriguez-Justo, Marnix Jansen

Authors Kai-Keen Shiu University College Hospital, NHS Foundation Trust, London, United Kingdom info_outline Kai-Keen Shiu, Yanrong Jiang, Mark Saunders, Jenny F. Seligmann, Timothy Iveson, Richard H. Wilson, Janet Shirley Graham, Khurum Hayat Khan, Anna-Maria Militello, Sandra Irvine, Temi Adedoyin, Rubina Begum, Reshma Bhat, William Wilson, Andrew Plumb, Austin Obichere, Manuel Rodriguez-Justo, Marnix Jansen Organizations University College Hospital, NHS Foundation Trust, London, United Kingdom, University College London Cancer Institute, London, United Kingdom, The Christie NHS Foundation Trust, Manchester, United Kingdom, University of Leeds, Leeds, United Kingdom, University Hospital Southampton, Southampton, United Kingdom, University of Glasgow, Glasgow, United Kingdom, Dept of Medical Oncology, Beatson West of Scotland Cancer Centre and University of Glasgow, Glasgow, United Kingdom, University College London Hospitals NHS Foundation Trust, London, United Kingdom, UCLH NHS Foundation Trust, London, London, United Kingdom, Cancer Research Advocates Forum , London, United Kingdom, Cancer Research UK & UCL Cancer Trials Centre, London, United Kingdom, UCL Cancer Trials Centre, London, United Kingdom, UCLH NHS Foundation Trust, London, United Kingdom, University College Hospital-London, London, United Kingdom Abstract Disclosures

Clinical